Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now

Buy Mphasis; target of Rs 3650: Emkay Global Financial

Emkay Global Financial is bullish on Mphasis has recommended buy rating on the stock with a target price of Rs 3650 in its research report dated February 25, 2022.

February 28, 2022 / 02:02 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Emkay Global Financial's report on Mphasis

Mr. Nitin Rakesh, CEO, and Mr. Manish Duggar, CFO, in an interaction with us, highlighted that cloud migration, data, core modernization and customer experience are major tech consumption trends, and the company’s investments have enabled it to capitalize on growth opportunities in those areas and sustain growth momentum. Focus on proactive large deal origination, client mining, new logo additions and a steady increase in deal sizes and tenure led to robust deal TCV wins and revenue conversion. Traction in BFSI, Hitech, Travel and Healthcare augurs well for sustainable growth. Mphasis remains confident of delivering organic EBITM within 15.5-17% in FY22. The integration of Blink will have an incremental 100bps negative impact for the first two years. It expects margins to remain stable with an upward bias, considering the offshore shift, flattening pyramid and lower dilutive impact from Blink, with growing revenue negating wage inflation.

Outlook

We retain Buy on Mphasis with a TP of Rs3,650 (33x Mar’24E EPS) on continued strength in the Direct business with stable margins. Overall revenue growth should converge with the Direct business as the share of the DXC business shrinks further.